Physiologically based pharmacokinetic modeling to predict complex drug–drug interactions: a case study of AZD2327 and its metabolite, competitive and time‐dependent CYP3A inhibitors

In conclusion, this model simulated DDI with less than a two‐fold error, indicating that complex clinical DDI associated with multiple mechanisms, pathways and inhibitors (parent and metabolite) can be predicted using a well‐developed PBPK model. Copyright © 2015 John Wiley & Sons, Ltd.

Source: Biopharmaceutics and Drug Disposition - July 27, 2015 Category: Drugs & Pharmacology Authors: Jian Guo, Diansong Zhou, Yan Li, Bui H. Khanh Tags: Original Paper Source Type: research